Vascular Biology Group
Our research aims to identify pathways linking inflammation and thrombosis and to develop novel therapeutics targeted to specific vascular beds.
We have developed novel endothelial-targeted therapeutics with specificity to activated vascular beds, thereby delivering benefit with minimal systemic bleeding compromise.
Our group is also developing state-of-the-art platforms based on microfluidic technology to screen chemical libraries for anti-thrombotic potential and develop point-of-care devices for the diagnosis and management of haemostatic disorders.
Our partners
News & articles
from Alfred Health
